Comparative Pharmacology
Head-to-head clinical analysis: SYNALGOS DC A versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALGOS DC A versus TALWIN.
SYNALGOS-DC-A vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYNALGOS-DC-A contains dihydrocodeine, which is a semisynthetic opioid agonist; aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes; and caffeine, a central nervous system stimulant. Dihydrocodeine binds to mu-opioid receptors in the central nervous system to produce analgesia. Aspirin irreversibly acetylates COX-1 and COX-2, reducing prostaglandin synthesis. Caffeine enhances analgesia via adenosine receptor antagonism and possibly by increasing drug absorption.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
1-2 capsules orally every 4-6 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours; clinical context: prolonged with hepatic impairment, age >60 years, and renal dysfunction; accumulation of norpropoxyphene may cause cardiotoxicity
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Renal: ~70-80% as free and conjugated propoxyphene; norpropoxyphene is renally eliminated; biliary: 10-20%; fecal: <10%
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic